Trinity Biotech Depreciation & Amortization Growth & History (TRIB)
Trinity Biotech's depreciation and amortization was $2.7M for fiscal 2025.
View full Trinity Biotech company overviewTrinity Biotech annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.7M | $2.5M | +1215.69% |
| 2024 | 2024-12-31 | $204,000 | $204,000 | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | −$38.0M | — |
| 2021 | 2021-12-31 | $38.0M | $38.0M | +94900.00% |
| 2020 | 2020-12-31 | $40,000 | $36,000 | +900.00% |
| 2019 | 2019-12-31 | $4,000 | −$75,000 | −94.94% |
| 2018 | 2018-12-31 | $79,000 | −$449,000 | −85.04% |
| 2017 | 2017-12-31 | $528,000 | $114,000 | +27.54% |
| 2016 | 2016-12-31 | $414,000 | $346,000 | +508.82% |
| 2015 | 2015-12-31 | $68,000 | — | — |
Trinity Biotech quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $424,000 | — | — |
Trinity Biotech depreciation and amortization trends
Over the last five fiscal years, Trinity Biotech's depreciation and amortization increased from $40,000 to $2.7M, a change of $2.6M. The latest reported quarter, Q4 2024, shows $424,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Trinity Biotech source filings ↗